We are seeking a Series A Round to produce and market our next generation HeartPartner.
See Investor Slide Deck below.

Sonostics develops, manufactures, and sells, non-invasive “second heart” pacemakers which correct the circulatory inadequacy caused by soleus muscle insufficiency. Based on technology initially created at, and exclusively licensed from, the State University of New York, our neuro-muscular stimulation technology, NeuroMod®, activates the soleus muscles (second hearts) deep in each calf, enhancing the return of blood and interstitial fluid from the lower extremities back to the heart. Soleus muscle activation results in increased cardiac output, and therefore, increased blood flow to all the tissues of the body.

Neuromod technology provides a non-invasive, non-drug, intervention for a variety of circulatory complications associated with second heart insufficiency. However, Sonostics’ primary market focus is health and wellness conditions associated with inadequate blood flow to the brain. This includes conditions such as age related cognitive decline, Parkinson Disease associated cognitive impairment, as well as attention deficit disorder observed in middle aged adults.

Sonostics works with primary healthcare providers who are confronted daily with cognitive impairment in their elderly patients. While cognitive impairment can arise for a variety of reasons, insufficient cerebral blood flow accounts for the majority of cases. For patients with both cognitive impairment and signs/symptoms of low cardiac output, the HeartPartner represents a highly effective, convenient, and low-cost, intervention. The HeartPartner II will be cleared as FDA Class II durable medical equipment, permitting Medicare reimbursement. Those over age 65 are at greatest risk of developing age related cognitive decline and by 2030 there will be over 73M Americans in this age group. These demographics suggest a total addressable market exceeding $60B in the U.S. alone.

Please contact our corporate offices using our Contact Form.